INTRODUCTION

Mechanisms of Antimicrobial Resistance in N. Gonorrhoeae
Gonorrhea, caused by the Gram-negative organism Neisseria gonorrhoeae, is the second most commonly reportable condition in the United States (US). In 2017, 555,608 cases of gonorrhea were reported to the Centers for Disease Control and Prevention (CDC) [1] . Since the 1930s, N. gonorrhoeae has developed resistance to all recommended antimicrobial therapies, greatly limiting the number of available treatment options [2] . Reduced susceptibility of gonococcal isolates to either cephalosporins or macrolides, the two most clinically relevant antimicrobials, is primarily attributed to alterations in several chromosomal genes. Cis-or trans-acting mutations impacting function or expression of the mtrR-repressor encoding gene product (MtrR) can elevate expression of the mtrCDE efflux pump operon resulting in decreased bacterial susceptibility to a broad range of antimicrobials, including beta-lactam and macrolide antibiotics [2, 13] . Additionally, amino acid changes in the MtrD transporter component of the MtrCDE efflux pump can enhance such resistance [13] , and point mutations in 23S rRNA can confer high-level resistance to azithromycin. Mutations in ribosomal proteins L4 and L22 encoded by the rplD and rplV genes, may confer resistance to macrolides by altering the conformation of the 23S rRNA domains, but this has not been reported in gonococcal isolates. Mutations in porB can decrease the influx of antibiotics, while point mutations in ponA (PBP1) and penA (PBP2) can decrease the acylation rate for beta-lactams, including third-generation cephalosporins.
Treatment Guideline Changes and Potential Selection of Antimicrobial Resistance
The Gonococcal Surveillance Isolate Project (GISP), a sentinel surveillance system of sexually transmitted disease (STD) clinics, monitors gonococcal antimicrobial resistance (AMR) in the US [4] . Reports from GISP indicated that isolates with elevated cefixime minimum inhibitory concentrations (MICs) (CFX em ; MIC ≥ 0.25 μg/mL) peaked at 1.4% nationally before CDC updated its treatment recommendations in 2012, but Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiz079/5351606 by University of california san diego user on 13 March 2019 A c c e p t e d M a n u s c r i p t 4 has since decreased to 0.4% in 2017 [4, 5, 6] . Since 2015, the first-line treatment option for uncomplicated gonococcal infections in the US has been 250 mg of ceftriaxone injected intramuscularly along with 1g of azithromycin taken orally [7] . During 2012-2017, isolates with elevated ceftriaxone MICs (CRO em ; MIC ≥ 0.125 μg/mL) fluctuated between 0.05% and 0.2%, while isolates with elevated azithromycin MICs (AZI em ; MICs ≥ 2 μg/mL) demonstrated a steady increase [4] . Only four isolates (Hawaii, 2016) collected through GISP have been documented with high-level azithromycin resistance (HL-AZI r ; MICs ≥ 256 µg/mL) and CRO em , however, no evidence of sustained transmission within Hawaii or elsewhere was observed [8] . Nevertheless, the recent global emergence of strains with resistance to extended spectrum cephalosporins (ESCs; i.e., cefixime and ceftriaxone), azithromycin, or both has raised concerns regarding a future of untreatable gonorrhea. History has shown that treatment guideline changes are often accompanied by the decline and subsequent rapid emergence of newly resistant strains. Therefore, we hypothesized that the 2012 change in treatment regimen may have selected uniquely resistant gonococcal strains.
Whole genome sequencing can facilitate the development of point-of-care tests for antimicrobial
resistance (AMR)
As the available options for the effective treatment of gonorrhea wane, there is an increased urgency to better understand the underlying molecular epidemiology of the disease in the United States (US) and abroad.
Whole genome sequencing methods have been shown to provide enhanced resolution over traditional typing methods in studies aimed at identifying and monitoring the spread of resistant gonococcal lineages [9, 10] .
Ultimately, data on the associations and stability of AMR markers can facilitate the development of rapid point of care (POC) diagnostic tests (e.g., nucleic acid amplification tests [NAAT] based, real-time PCR, etc.), which may inform treatment and prevention strategies. 
MATERIALS AND METHODS
Isolate and antimicrobial susceptibility testing (AST)
This study included 649 male urethral N. gonorrhoeae isolates collected by GISP (January 2014 to December 2016 Elevated MIC interpretations were based on established criteria for GISP isolates [4] .
WGS and sequence analysis
DNA prepared from 649 N. gonorrhoeae isolates was sequenced (paired-end, 2 X 250-bp) on an Illumina MiSeq sequencer (Illumina Denmark ApS, Copenhagen, Denmark), and WGS read data were submitted to the NCBI BioProject PRJNA317462 (Supplemental Data). Quality assessment was performed using FastQC 0.10.1 and reads were de-novo assembled using Spades 2.5.1 [15] . KmerGenie was used when the assemblies exceeded 150 contigs [16, 17] . Contaminants were identified using Kraken 0.10.5 [18] . A core genome single-nucleotide polymorphism (SNP) alignment was computed in ParSNP v1.2 using the FA19 reference strain (GenBank accession no. CP012026) [19] . A maximum likelihood phylogenetic tree was generated using RaxML v8.2.9 [21] . See the Supplementary Methods for further details of analysis of MLST, NG-MAST, AMR determinants, and phylogenies. Fisher's exact or χ 2 test were used to determine the association between mutational patterns, STs, sex with sex partner, or clades with respect to elevated MICs respective of each antibiotic [25] . P values and 95%
CIs were used to determine statistical significance. A Bonferonni correction was applied for multiple tests. A c c e p t e d M a n u s c r i p t 9 by an A-deletion in mtrR promoter, H105Y in mtrR coding region, ponA L421P, and porB G120K/A121N or A121D. The four isolates from Hawaii [8] with HL-AZI r also possessed elevated ceftriaxone MICs. In addition to the A-deletion in the mtrR promoter and A2059G mutation, all four isolates contained the G120K/A121D mutation in porB, a non-mosaic PBP2 pattern XVIII with the A501T mutation, and the ponA L421P mutation.
Statistical analyses
These were the only isolates with a dually elevated MIC phenotype (HL-AZI/CRO em ). Elevated cephalosporin
MICs were also observed in smaller clades, dispersed throughout the phylogenetic tree. The clades containing isolates with elevated cephalosporin MICs including their average intra-clade SNP distances, are summarized in Table 1 .
The complete nucleotide sequences of the penA alleles were compared to reference sequence M32091.1
[26]. The frequency of PBP2 patterns for cefixime and ceftriaxone with respect to MICs are presented in Tables   4-5 . In total, seven unique amino acid sequence patterns were identified for isolates with elevated MICs to either cefixime or ceftriaxone including non-mosaic patterns (XII, XIII, XVIII, and LXVIII) and mosaic patterns (X, XXXIV, and LXXI) (Supplemental Figure 4) . A significant association was observed between with CFX em and PBP2 pattern XXXIV (53%, 24/45, P < 0.0001) and LXXI (9%, 4/45, P < 0.0001). PBP2 pattern XIII (12%, 3/25, P < 0.0001) and XVIII (16%, 4/25, P < 0.0001) were significantly associated with CRO em .
Only isolates with the PBP2 pattern X displayed a significant association with both elevated cefixime (24%, 11/45, P < 0.0001) and ceftriaxone MICs (28%, 7/25, P < 0.0001). Eight isolates with pattern XIII and the A501V alteration clustered clonally in Clade I; while four other isolates within Clade B contained pattern XVIII with the A501T alteration [27, 28] .
An adenine deletion in the mtrR promoter was significantly associated with isolates with CFX em (89%, 40/45; P < 0.0001) and CRO em (92%, 23/25; P < 0.0001) MICs. Additionally, we examined combinations of mutations in the mtr locus with respect to either cephalosporin ( A c c e p t e d M a n u s c r i p t 10 carried the A39T, R44H mutations [29] . The G45D mutation was significantly associated only with CRO em isolates that also possessed the A-deletion in the mtrR promoter (36%, 9/25, P < 0. A c c e p t e d M a n u s c r i p t 11 contrast to mutations in GISP isolates from previous years (2000-2013) as identified in an earlier study [9] . In that study it was reported that AZI em was primarily attributed to mutations in 23S rRNA alleles (165/294, 56%), Recent work has shown the C-substitution reduces mtrR expression [29] . Interestingly, this substitution also Warner et al demonstrated that mutations in the mtr locus that affect expression of the mtrCDE efflux pump confer fitness advantages over wild-type strains in vivo [31] . Importantly, this may explain why the MLST ST9363 lineage exhibited a sustained temporal persistence and a high degree of spatial heterogeneity across multiple regions within the United States over all the years investigated. Highlighting a similar trend observed in GISP, many of the AZI em isolates in this clade significantly associated with MSM (62%, 118/198; P < 0.0001), and were highly homogenous having 96 out of 132 AZI em isolates with a relatively close SNP distance (39.94 ± 14.65 SNPs) [36] . These data may have important implications as recent studies have reported a higher prevalence of azithromycin-resistant gonococci amongst networks of MSM [37, 38] . ± 17.42 SNPs) and H (n = 3, 4 ± 1.79 SNPs) represented by MLST ST1901 and ST7822 respectively [35] .
Although, the four Hawaiian (2016) isolates (79.50 ± 17.42 SNPs) represented by MLST ST1901 were contained, the fact it possessed HL-AZI r is particularly worrisome because this multidrug-resistant gonococcal clone has been attributed to most of the elevated cephalosporin MICs observed globally [21] . Despite, the limited number of HL-AZI r isolates observed between 2014-2016, a recent study [36] demonstrated that the A2059G mutation can enhance the in vivo biological fitness of N. gonorrhoeae, and when combined with the sporadic global emergence of HL-AZI clusters illustrate the growing concerns over continued use of azithromycin [8, 34, 37, 38] . (e.g., X and XXXIV) previously described in earlier studies in addition to lesser known patterns such as LXVIII, LXXI [28, 44, 45] . Similar to a previous study, CFX em isolates with PBP2 pattern XXXIV (61%, 17/28)
Cefixime/ Ceftriaxone
were observed circulating amongst MSM [46] . Isolates with non-mosaic PBP2 patterns such as XII and XIII, which contain short modified segments likely originating from other Neisseria spp., in addition to mutations in other genes (i.e., mtrR, porB, ponA), also possessed the ESC em phenotype [43, 44] . Although, resistance mutations in mosaic penA alleles can reduce the in vitro and in vivo fitness of cephalosporin resistant strains, compensatory mutations in other genes (i.e. mtrR, acnB and mleN) can be selected that restore fitness, thus allowing these strains to spread [45] [46] [47] . The combined effects of compensatory mutations in these secondary loci in addition to mutations in porB and ponA may explain why CFX em and CRO em isolates with non-mosaic penA alleles can also spread despite these alleles not being associated with ESC em on an individual basis [44] . In support of this, a closer inspection of metabolic genes revealed that the acnB Q371K mutation was frequently present in CFX em strains (53%, 24/45, P < 0.0001), however neither the acnB G348D or mleN A465 codon deletion as reported by Vincent et al were detected (Supplemental Figures 6 and 7 ) [29] . Furthermore, we found that mutations in other genes (e.g., ponA L421P substitution, A-deletion in mtrR promoter, H105Y mutation in mtrR, and a double mutation in porB at the G120 and A121 positions) were often present (P < 0.0001) in ESC em strains regardless of the mosaicity of the penA allele or lack thereof [23] . These results suggest that any future molecular diagnostic tests will need to consider several mutational combinations in order to reliably predict ESC em .
There are several limitations to this study. First, isolates are collected only from men with symptoms of urethral gonorrhea diagnosed at participating STD clinics, and therefore may not fully represent all gonorrhea diagnosed in the United States. Second, although the final sequenced data set for this study was a sample of all A c c e p t e d M a n u s c r i p t 14 GISP isolates collected during the time period, by design it over represented isolates with elevated MICs (e.g., 49% of sequenced isolates had elevated MICs to AZI versus 3% in the full GISP dataset). However, among susceptible isolates and those with elevated MICs, the sequenced sample provided a reasonable representation of isolates observed through GISP over the years and across HHS regions (Supplemental Table 1 ). Finally, because whole genome sequencing of gonococcal isolates is conducted on subcultures from a single-colony isolated from subcultures of frozen isolates it does not provide any context to the susceptibilities or genetic diversity of the entire gonococcal population during infection [51] . This may be especially pertinent in patient cases involving mixed infections [49, 50] .
Overall, our analyses suggest a relatively recent evolution of several gonococcal strains that possess mutations that were not observed in the United States, 2000-2013 [9] . The emergence of these mutational patterns may be explained by recent interspecies recombination with other commensal Neisseria species (e.g.,
N. lactamica and/or meningitidis), various selective pressures (e.g., host environment and continued antibiotic usage), or both [3, 10, 34, 43] . This impact appeared to be most profound in AZI em isolates, particularly of MLST ST9363, where we detected evidence of horizontally acquired variants throughout the mtr locus, mtrD, and elsewhere in rplD. Conversely, ESC em isolates displayed multiple PBP2 patterns that had not been reported prior to 2014, therefore future studies utilizing WGS should consider prioritizing compensatory mutations identified in fitness studies for further examination. Changes in the diversity and distribution in several antimicrobial resistance determinants in a relatively short period highlight the need for routine molecular surveillance in order to identify and respond to circulating gonococcal strains with antimicrobial resistance. Table 2 . Molecular markers associated with elevated azithromycin MICs among GISP N. gonorrhoeae isolates collected from 2014 to 2016. Promoter variant includes A-deletion (n = 246) and C-substitution (n = 133) in inverted repeat. Mosaic mtrR coding region determined by alignment to the reference KT954125 mosaic mtrR coding sequence using a similarity threshold of 98%. 
